U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2P.3Zn
Molecular Weight 258.175
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZINC PHOSPHIDE

SMILES

[P-3].[P-3].[Zn++].[Zn++].[Zn++]

InChI

InChIKey=IGSZOEHCOKSBEI-UHFFFAOYSA-N
InChI=1S/2P.3Zn/q2*-3;3*+2

HIDE SMILES / InChI
Molecular Formula Zn
Molecular Weight 65.409
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula HP
Molecular Weight 31.9817
Charge -2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Sources: http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783http://www.t3db.ca/toxins/T3D0733https://www.google.com/patents/US3130034https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.hmdb.ca/metabolites/HMDB01303http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttps://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459
Curator's Comment: description was created based on several sources, including http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicity

Zinc monocarbonate (Zinc Carbonate) is an inorganic salt. In the United States, Zinc Carbonate may be used as an active ingredient in OTC drug products. When used as an active drug ingredient, the established name is Zinc Carbonate. Zinc monocarbonate is generally recognized as safe by FDA. It is used as skin protectant active ingredient. Zinc carbonate was found to retard the degradation of some poly(lactide-co-glycolide) (PLG) microspheres in vivo and in vitro. Adding Zinc Carbonate is essential during the preparation of PLGA microspheres. It can remarkably improve the stability of drugs in the acid microenvironment inside PLGA microspheres.

CNS Activity

CNS Active
3913
Curator's Comment: Spatial memory deficits in a mouse model of late-onset Alzheimer's disease were caused by Zinc Carbonate supplementation. Long-term dietary administration of zinc ( Zinc Carbonate) can lead to impairments in cognitive function in rats. Microprobe synchrotron X-ray fluorescence (microSXRF) confirmed that brain zinc levels were increased by adding Zinc Carbonate to the drinking water.

Originator

Smithson, R.
38
Curator's Comment: Protherics that initially developed Voraxaze was acquired by BTG International in 2008. After the acquisition BTG International completed the development of Voraxaze and submitted the product for US approval.

Approval Year

1921
1467
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Activator
1430
Activator
1430
Hydrolytic Enzyme
38
ultraviolet B-induced damage
38
Target ID: ultraviolet B-induced damage
Interacts
323
Activator
1430
Zinc transporter ZIP1
38
Target ID: Q9NY26
Gene ID: 27173.0
Gene Symbol: SLC39A1
Target Organism: Homo sapiens (Human)
Binding Agent
1064
Zinc transporter ZIP2
38
Target ID: Q9NP94
Gene ID: 29986.0
Gene Symbol: SLC39A2
Target Organism: Homo sapiens (Human)
Binding Agent
1064
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Basic research
Unknown

Approved Use

Unknown
Primary
Approved
8429
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

1955
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Secondary
Approved
8429
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

2012
Primary
Approved
8429
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

2006
Primary
Approved
8429
ZINC OXIDE

Approved Use

Unknown
Primary
Approved
8429
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
Phase III
656
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
Phase III
656
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
PubMed

PubMed

TitleDatePubMed
Quadrupolar perturbed 14N NMR in the structurally commensurate and incommensurate phases of ammonium tetrachlorozincate.
1991 Apr 1
New applications for the zinc iodide-osmium tetroxide technique.
1994 Feb
Thujaplicin-copper chelates inhibit replication of human influenza viruses.
1998 Aug
Effects of trace metal compounds on HIV-1 reverse transcriptase: an in vitro study.
1999 May
Inhibition of HIV-1 infection by zinc group metal compounds.
1999 Sep
Combined effects of argon laser irradiation and fluoride treatments in prevention of caries-like lesion formation in enamel: an in vitro study.
1999 Spring
Zinc-induced anti-apoptotic effects in SH-SY5Y neuroblastoma cells via the extracellular signal-regulated kinase 1/2.
2005 Apr 27
Characterization and inhibition of SARS-coronavirus main protease.
2006
Effect of end-stage renal disease and diabetes on zinc and copper status.
2006 Jul
Seminal plasma zinc concentration and alpha-glucosidase activity with respect to semen quality.
2006 May
Marginal zinc deficiency increased the susceptibility to acute lipopolysaccharide-induced liver injury in rats.
2006 May
Role of the dissolved zinc ion and reactive oxygen species in cytotoxicity of ZnO nanoparticles.
2010 Dec 15
Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells.
2011 Jul
Responses of human cells to ZnO nanoparticles: a gene transcription study.
2011 Nov
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012 Apr
Zinc oxide nanoparticles-induced intercellular adhesion molecule 1 expression requires Rac1/Cdc42, mixed lineage kinase 3, and c-Jun N-terminal kinase activation in endothelial cells.
2012 Mar
Distinct immunomodulatory effects of a panel of nanomaterials in human dermal fibroblasts.
2012 May 5
Glucarpidase for the treatment of life-threatening methotrexate overdose.
2012 Nov
Zinc oxide nanoparticles inhibit Ca2+-ATPase expression in human lens epithelial cells under UVB irradiation.
2013 Dec
TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils.
2013 Jul 31
Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells.
2013 Mar
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.
2013 Nov 25
Involvement of MyD88 in zinc oxide nanoparticle-induced lung inflammation.
2013 Sep
Mechanism of uptake of ZnO nanoparticles and inflammatory responses in macrophages require PI3K mediated MAPKs signaling.
2014 Apr
Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles.
2014 Jan
Additive effect of zinc oxide nanoparticles and isoorientin on apoptosis in human hepatoma cell line.
2014 Mar 3
Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy.
2014 May
Synthesis aspects, structural, spectroscopic, antimicrobial and room temperature ferromagnetism of zinc iodide complex with Schiff based ligand.
2015 Jan 25
Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations.
2016 Sep 21
Patents

Patents

04005147
106
04090844
38
04134847
38
04292237
38
04376079
39
04377675
40
04404196
40
04565693
38
04670586
38
04740363
38
04743435
42
04904401
38
04950702
42
05064815
38
05149745
38
05442047
38
05539121
38
05646324
38
05773011
38
05911978
38
06140331
38
06303833
38
06706904
38
07375243
38
07585885
44
07799339
38
07959530
39
08258190
38
20060128799
38
20060270867
38
20070213331
40
20070249787
39
20080274173
38
20090092554
38
20100048844
38
20100117110
38
20100324259
38
7632959
38
CN105567322
38
EP0119068A1
38
US1767667
38
US20070265374
38
US2522537
38
US2537262
38
US3248354
38
US3453072
38
US3790469
38
US6853140
38

Sample Use Guides

In Vivo Use Guide
Rats: The dosage of zinc fluoride tetrahydrate (ZnF2 •4H2O) was adjusted to contain 2.1 mg (low-dose group, LG), 4.3 mg (mid-dose group, MG), and 5.4 mg fluoride per 200 g rat body weight (high-dose group, HG) corresponding to 5, 10, and 12.5 % of LD50 values for NaF.
Route of Administration: Oral
In Vitro Use Guide
Prepared ground human enamel specimens were immersed in zinc fluoride solutions containing 250 and 750 ppm F- at pH 6 and 4 for 4 min.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:38:32 GMT 2023
Edited
by admin
on Fri Dec 15 15:38:32 GMT 2023
Record UNII
813396S1PC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZINC PHOSPHIDE
HSDB   ISO   MI   WHO-DD  
Common Name English
ZINC PHOSPHIDE [ISO]
Common Name English
Zinc phosphide [WHO-DD]
Common Name English
ZINC PHOSPHIDE [HSDB]
Common Name English
ZINCUM PHOSPHORATUM [HPUS]
Common Name English
TRIZINC DIPHOSPHIDE
Common Name English
ZINC PHOSPHIDE (ZN(SUB 3)P(SUB 2))
Common Name English
ZINCUM PHOSPHORATUM
HPUS  
Common Name English
ZINC PHOSPHIDE [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C737
Created by admin on Fri Dec 15 15:38:32 GMT 2023 , Edited by admin on Fri Dec 15 15:38:32 GMT 2023
Code System Code Type Description
MESH
C009701
Created by admin on Fri Dec 15 15:38:32 GMT 2023 , Edited by admin on Fri Dec 15 15:38:32 GMT 2023
PRIMARY
EPA CompTox
DTXSID1024386
Created by admin on Fri Dec 15 15:38:32 GMT 2023 , Edited by admin on Fri Dec 15 15:38:32 GMT 2023
PRIMARY
ECHA (EC/EINECS)
215-244-5
Created by admin on Fri Dec 15 15:38:32 GMT 2023 , Edited by admin on Fri Dec 15 15:38:32 GMT 2023
PRIMARY
RXCUI
1594583
Created by admin on Fri Dec 15 15:38:32 GMT 2023 , Edited by admin on Fri Dec 15 15:38:32 GMT 2023
PRIMARY RxNorm
NCI_THESAURUS
C77382
Created by admin on Fri Dec 15 15:38:32 GMT 2023 , Edited by admin on Fri Dec 15 15:38:32 GMT 2023
PRIMARY
MERCK INDEX
m11622
Created by admin on Fri Dec 15 15:38:32 GMT 2023 , Edited by admin on Fri Dec 15 15:38:32 GMT 2023
PRIMARY Merck Index
PUBCHEM
25113606
Created by admin on Fri Dec 15 15:38:32 GMT 2023 , Edited by admin on Fri Dec 15 15:38:32 GMT 2023
PRIMARY
HSDB
1059
Created by admin on Fri Dec 15 15:38:32 GMT 2023 , Edited by admin on Fri Dec 15 15:38:32 GMT 2023
PRIMARY
WIKIPEDIA
ZINC PHOSPHIDE
Created by admin on Fri Dec 15 15:38:32 GMT 2023 , Edited by admin on Fri Dec 15 15:38:32 GMT 2023
PRIMARY
FDA UNII
813396S1PC
Created by admin on Fri Dec 15 15:38:32 GMT 2023 , Edited by admin on Fri Dec 15 15:38:32 GMT 2023
PRIMARY
ALANWOOD
zinc phosphide
Created by admin on Fri Dec 15 15:38:32 GMT 2023 , Edited by admin on Fri Dec 15 15:38:32 GMT 2023
PRIMARY
DAILYMED
813396S1PC
Created by admin on Fri Dec 15 15:38:32 GMT 2023 , Edited by admin on Fri Dec 15 15:38:32 GMT 2023
PRIMARY
CAS
1314-84-7
Created by admin on Fri Dec 15 15:38:32 GMT 2023 , Edited by admin on Fri Dec 15 15:38:32 GMT 2023
PRIMARY
Related Record Type Details
Structure of ZINC CATION
PARENT -> SALT/SOLVATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966